Abbott Laboratories
ABT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000001800
In the last 90 days, Abbott Laboratories insiders filed 0 open-market purchases and 3 sales; 2,986 institutions reported holding it in 13F filings for Q2 2026, worth $125.2B in total; 3 superinvestors hold it, including Southeastern Asset Management (Longleaf) and Soros Fund Management.
Q2 2022 vs. Q1 2022
How the institutions holding Abbott Laboratories changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 2,766 | 36 | 2,703 | −27 |
| Shares | 1.29B | 10.3M | 1.29B | +9.81M (+0.8%) |
| Value | $152.9B | $1.23B | $140.6B | −$11.1B (−7.3%) |
36 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (96)
Institutions that held Abbott Laboratories at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (123)
Institutions that held Abbott Laboratories at the end of Q1 2022 and filed for Q2 2022 without it.
Showing the largest 100 of 123 by value.
Not filed for Q2 2022 yet (36)
Institutions that held Abbott Laboratories at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.